22
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      SARS-CoV-2 related liver impairment – perception may not be the reality

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To the Editor With the emergence of novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) related disease (Covid-19) pandemic with catastrophic consequences, large volumes of research from epicentres of infection have focussed on Covid-19 related liver impairment. In this regard, the study by Wang et al. published in the Journal intrigued us.(1) The authors associate very minimal elevations in alanine (ALT) and aspartate aminotransferase (AST; ALT > AST) to disease severity and demonstrate ‘specific’ findings of Covid-19 related cytopathic changes and virus-like particles on post-mortem liver histopathology (n=2).They found that SARS-Cov-2 caused massive apoptosis and binucleation of hepatocytes, resulting in liver enzyme abnormality and synthetic liver dysfunction, the latter in the form of hypoalbuminemia. Their painstaking work is commendable, but the perception and surmise of clinical and investigational events may not be quite the reality. It is recommended that the ideal cut-off for diagnosing acute hepatic injury is 200 U/L and 300 U/L for AST and ALT respectively.(2) The degree of elevation in AST and ALT in the current study can only be considered an ‘altered’ liver test, not akin to acute hepatic injury. In hepatic impairment, there must be very clear evidence for metabolic (hypoglycaemia, hyperammonemia), secretory (hyperbilirubinemia) and synthetic (hypoalbuminemia, raised prothrombin time) dysfunction. Except for a mild rise in ALT and hypoalbuminemia, significant liver dysfunction is elusive in the current study. Importantly, hypoalbuminemia, in the absence of other significant liver test abnormalities, virtually rules out the hepatic origin of this abnormality. Acute liver injury is best identified by international normalized ratio (INR) >2.0 which was conspicuously absent in the current study.(3) The liver biopsy findings of hepatocyte apoptosis, binuclear or occasional multinuclear syncytial hepatocytes, in the absence of viral inclusions and presence of moderate steatosis, with mild focal lobular or portal inflammation are non-specific findings that may not be related to viral cytopathy. These findings can be undoubtfully seen in sepsis and multi-organ dysfunction associated with critical illness (moderate to severe apoptosis, steatosis, lobular and portal inflammation) and aging, sepsis, drug-induced liver injury and fatty liver disease (binucleation or polyploidy– a feature of liver cell renewal and not injury).(4, 5, 6) The liver biopsy does not correlate with increased gamma-glutamyl transpeptidase, which could have been secondary to the systemic illness or drug toxicity. CD68+ cellular infiltration of the hepatic sinusoids (a marker of macrophage activation) can be noted in any acute or chronic systemic inflammatory state affecting the liver, including metabolic-syndrome associated fatty liver disease (MAFLD). (7) Finally, the ‘spiked’ inclusions and their degenerate components may not be of viral origin since the confirmatory polymerase chain reaction testing for viral nucleic acids was not performed. Such ‘corona-like’ particles could be intrahepatic cholesterol crystals, lamellations, or ‘crown-like’ structures seen in patients with MAFLD. In the latter, Kupffer cells surround and engulf remnant lipid droplets (themselves granular or spiky cytoplasmic inclusions) of apoptotic hepatocytes. Moreover, associating mitochondrial changes to SARS-CoV-2 infection of hepatocytes could be erroneous. Electron microscopic changes of liver mitochondria in the form of enlarged mitochondria, intramitochondrial crystalline inclusions, mitochondrial matrix granules, vesicles containing electron-dense material in peribiliary Golgi-zone and electron-dense material accumulation in the space of Disse are notable in steatotic livers and drug-induced liver injury. (8, 9). In non-hepatotropic viral infection, such as cytomegalovirus-hepatitis, the liver involvement occur as part of the disseminated systemic disease or secondary organ dysfunction that could be true for the SARS-CoV-2.(10) To conclude, even though intriguing, the study by Wang et al. might have suffered unintentional, but unfounded assumptions of SARS-CoV-2 related liver injury. Hepatic impairment is not confirmed, and multiple viral cytopathic effects described on liver histology may be misleading in presence of high age and multiple comorbidities. The use of ‘Covid-19 induced liver injury’ may be illusory, and its use needs caution. Current research has not confirmed direct SARS-CoV-2 related liver injury, and the features described may only suggest hepatic involvement of severe systemic inflammatory disease with or without sepsis driven by Covid-19.

          Related collections

          Most cited references9

          • Record: found
          • Abstract: found
          • Article: not found

          SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19

          Background Liver enzyme abnormality is common in patients with coronavirus disease 2019 (COVID-19). Whether or not SARS-CoV-2 infection can lead to liver damage per se remains unknown. Here we reported the clinical characteristics and liver pathological manifestations of COVID-19 patients with liver enzyme abnormality. Methods We received 156 patients diagnosed of COVID-19 from two designated centers in China, and compared clinical features between patients with elevated aminotransferase or not. Postmortem liver biopsies were obtained from two cases who had elevated aminotransferase. We investigated the patterns of liver impairment by electron microscopy, immunohistochemistry, TUNEL assay, and pathological studies. Results 64 of 156 (41.0%) COVID-19 patients had elevated aminotransferase. The median levels of ALT were 50 U/L vs. 19 U/L, respectively, AST were 45.5 U/L vs. 24 U/L, respectively in abnormal and normal aminotransferase groups. The liver enzyme abnormality was associated with disease severity, as well as a series of laboratory tests including higher A-aDO2, higher GGT, lower albumin, decreased CD4+ T cells and B lymphocytes. Ultrastructural examination identified typical coronavirus particles characterized by spike structure in cytoplasm of hepatocytes in two COVID-19 cases. SARS-CoV-2 infected hepatocytes displayed conspicuous mitochondrial swelling, endoplasmic reticulum dilatation, and glycogen granule decrease. Histologically, massive hepatic apoptosis and a certain binuclear hepatocytes were observed. Taken together, both ultrastructural and histological evidence indicated a typical lesion of viral infection. Immunohistochemical results showed scanty CD4+ and CD8+ lymphocytes. No obvious eosinophil infiltration, cholestasis, fibrin deposition, granuloma, massive central necrosis, or interface hepatitis were observed. Conclusions SARS-CoV-2 infection in liver is a crucial cause of hepatic impairment in COVID-19 patients. Hence, a surveillance of viral clearance in liver and long outcome of COVID-19 is required.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis.

            We sought to determine whether hepatic cholesterol crystals are present in patients or mice with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NASH), and whether their presence or distribution correlates with the presence of NASH as compared with simple steatosis. We identified, by filipin staining, free cholesterol within hepatocyte lipid droplets in patients with NASH and in C57BL/6J mice that developed NASH following a high-fat high-cholesterol diet. Under polarized light these lipid droplets exhibited strong birefringence suggesting that some of the cholesterol was present in the form of crystals. Activated Kupffer cells aggregated around dead hepatocytes that included strongly birefringent cholesterol crystals, forming "crown-like structures" similar to those recently described in inflamed visceral adipose tissue. These Kupffer cells appeared to process the lipid of dead hepatocytes turning it into activated lipid-laden "foam cells" with numerous small cholesterol-containing droplets. In contrast, hepatocyte lipid droplets in patients and mice with simple steatosis did not exhibit cholesterol crystals and their Kupffer cells did not form crown-like structures or transform into foam cells. Our results suggest that cholesterol crystallization within hepatocyte lipid droplets and aggregation and activation of Kupffer cells in crown-like structures around such droplets represent an important, novel mechanism for progression of simple steatosis to NASH.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Central role of mitochondria in drug-induced liver injury.

              A frequent mechanism for drug-induced liver injury (DILI) is the formation of reactive metabolites that trigger hepatitis through direct toxicity or immune reactions. Both events cause mitochondrial membrane disruption. Genetic or acquired factors predispose to metabolite-mediated hepatitis by increasing the formation of the reactive metabolite, decreasing its detoxification, or by the presence of critical human leukocyte antigen molecule(s). In other instances, the parent drug itself triggers mitochondrial membrane disruption or inhibits mitochondrial function through different mechanisms. Drugs can sequester coenzyme A or can inhibit mitochondrial β-oxidation enzymes, the transfer of electrons along the respiratory chain, or adenosine triphosphate (ATP) synthase. Drugs can also destroy mitochondrial DNA, inhibit its replication, decrease mitochondrial transcripts, or hamper mitochondrial protein synthesis. Quite often, a single drug has many different effects on mitochondrial function. A severe impairment of oxidative phosphorylation decreases hepatic ATP, leading to cell dysfunction or necrosis; it can also secondarily inhibit ß-oxidation, thus causing steatosis, and can also inhibit pyruvate catabolism, leading to lactic acidosis. A severe impairment of β-oxidation can cause a fatty liver; further, decreased gluconeogenesis and increased utilization of glucose to compensate for the inability to oxidize fatty acids, together with the mitochondrial toxicity of accumulated free fatty acids and lipid peroxidation products, may impair energy production, possibly leading to coma and death. Susceptibility to parent drug-mediated mitochondrial dysfunction can be increased by factors impairing the removal of the toxic parent compound or by the presence of other medical condition(s) impairing mitochondrial function. New drug molecules should be screened for possible mitochondrial effects.
                Bookmark

                Author and article information

                Contributors
                Journal
                J Hepatol
                J. Hepatol
                Journal of Hepatology
                European Association for the Study of the Liver. Published by Elsevier B.V.
                0168-8278
                1600-0641
                23 May 2020
                23 May 2020
                Affiliations
                [1]The Liver Unit and Monarch, Cochin Gastroenterology Group, Ernakulam Medical Center Hospital, Kochi, Kerala, India
                [2]Gastroenterology and Advanced GI Endoscopy, Cochin Gastroenterology Group, Ernakulam Medical Center Hospital, Kochi, Kerala, India
                [3]Gastroenterology and Advanced GI Endoscopy, Cochin Gastroenterology Group Ernakulam Medical Center Hospital Kochi, Kerala, India
                Author notes
                [] Corresponding Author: Cyriac Abby Philips M.D., D.M. The Liver Unit and Monarch Cochin Gastroenterology Group Ernakulam Medical Center Hospital Kochi, Kerala, India abbyphilips@ 123456gmail.com
                Article
                S0168-8278(20)30344-5
                10.1016/j.jhep.2020.05.025
                7255210
                32454042
                90a88ddf-d379-4048-b323-70518cce33c5
                © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 11 May 2020
                : 14 May 2020
                : 16 May 2020
                Categories
                Article

                Gastroenterology & Hepatology
                coronavirus,covid-19,pandemic,hepatitis,liver disease,dili,critical illness
                Gastroenterology & Hepatology
                coronavirus, covid-19, pandemic, hepatitis, liver disease, dili, critical illness

                Comments

                Comment on this article